Skip to main content

Table 3 Multivariate regression analyses of local and systemic reactions reported in the short-term surveys

From: Reactogenicity and safety of COVID-19 primary immunisation and booster vaccination regimens: a comparative observational cohort study

 

Local reactions 14  days after the vaccination

Systemic reactions 14  days after the vaccination

OR

95% CI

p-value

OR

95% CI

p-value

LL

UL

LL

UL

First vaccination (n  = 3060, reference = BNT162b2)

 Intercept

3.01

2.28

3.85

 < 0.0001

1.82

1.40

2.35

 < 0.0001

 mRNA-1273

2.05

1.69

2.51

 < 0.0001

1.48

1.24

1.78

 < 0.0001

 ChAdOx1

1.10

0.80

1.53

0.5536

6.41

4.31

9.80

 < 0.0001

 Ad26.COV2-S

0.68

0.49

0.96

0.0278

4.21

2.86

6.36

 < 0.0001

 Age

0.97

0.97

0.98

 < 0.0001

0.97

0.97

0.98

 < 0.0001

 Female

2.09

1.79

2.44

 < 0.0001

1.80

1.54

2.10

 < 0.0001

 mSCQ

1.05

0.99

1.10

0.0878

1.19

1.13

1.25

 < 0.0001

 Interval V-R

1.01

0.99

1.04

0.3121

1.03

1.01

1.05

0.0153

Second vaccination (n  = 9124, reference = BNT162b2 + BNT162b2)

 Intercept

3.46

2.65

4.52

 < 0.0001

7.05

5.28

9.44

 < 0.0001

 mRNA-1273 − mRNA-1273

3.10

2.68

3.59

 < 0.0001

3.80

3.23

4.48

 < 0.0001

 ChAdOx1 − ChAdOx1

0.57

0.42

0.76

0.0019

1.13

0.83

1.55

0.4262

 ChAdOx1 − BNT162b2

1.49

1.19

1.88

0.0057

2.97

2.31

3.85

 < 0.0001

 ChAdOx1 − mRNA-1273

3.18

2.40

4.22

 < 0.0001

5.57

4.06

7.69

 < 0.0001

 Age

0.97

0.97

0.97

 < 0.0001

0.97

0.96

0.97

 < 0.0001

 Female

2.12

1.93

2.32

 < 0.0001

1.98

1.80

2.18

 < 0.0001

 mSCQ

1.09

1.06

1.12

 < 0.0001

1.12

1.09

1.16

 < 0.0001

 Interval V-R

1.01

1.00

1.01

 < 0.0001

1.01

1.01

1.01

 < 0.0001

 Interval to 2nd dose

1.00

0.99

1.00

0.379

0.99

0.98

1.00

0.0059

Third vaccination (n  = 2241, reference = PI mRNA + BNT162b2)

 Intercept

2.32

1.72

3.14

 < 0.0001

3.37

2.48

4.59

 < 0.0001

 PI mRNA + mRNA-1273

2.33

1.87

2.91

 < 0.0001

2.48

1.98

3.10

 < 0.0001

 PI vector + BNT162b2

1.08

0.67

1.73

0.7605

0.87

0.54

1.41

0.5810

 PI vector + mRNA-1273

1.27

0.73

2.20

0.3991

1.87

1.07

3.34

0.0293

 PI mRNA/vector + BNT162b2

1.07

0.78

1.47

0.6678

1.41

1.02

1.96

0.0408

 PI mRNA/vector + mRNA-1273

1.82

1.32

2.51

0.0003

1.87

1.36

2.59

0.0001

 Age

0.97

0.97

0.98

 < 0.0001

0.96

0.96

0.97

 < 0.0001

 Female

1.98

1.66

2.38

 < 0.0001

1.69

1.41

2.03

 < 0.0001

 mSCQ

1.10

1.04

1.17

0.0015

1.13

1.06

1.20

0.0002

 Interval V-R

1.01

0.98

1.04

0.5416

1.05

1.02

1.08

0.0016

  1. CI confidence interval, LL lower limit, UL upper limit, interval V-R interval between vaccination and registration to the study, PI mRNA PI with BNT162b2 or mRNA-1273, PI vector PI with ChAdOx1. PI mRNA/vector PI with BNT162b2 or mRNA-1273 and ChAdOx1. Age in years, reference gender: male (divers: excluded due to small n), mSCQ: continuous variable, interval in days. Participants excluded from analysis: gender = divers: first vaccination: n = 3, second: n = 8, third: n = 1; NA for “interval to 2nd dose: second vaccination: n = 2)
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us